Replies to post #222454 on Biotech Values

[dewophile]

CEO Dan Browne said on a recent webcast that a larger proportion of SAKURA-3 patients than originally expected opted to be treated with RT002 a second time

That's certainly good news. I always felt that a good safety profile would be the base case in this trial but perhaps other data like pt satisfaction etc. (and more confirmation on extended duration) could end up as a nice added plus

[DewDiligence]

RVNC’s latest slide set (for ISI and PJ webcasts this week):

https://investors.revance.com/static-files/8a30eb4e-60ec-4bc2-9555-e00c4ccd4797